Protein-reactive metabolites of carbamazepine in mouse liver microsomes

Drug Metabolism and Disposition

Volumn 24, Issue 5, 1996, Pages 509-514

  Lillibridge, J H ^a   Amore, B M ^a   Slattery, J T ^a   Kalhorn, T F ^a   Nelson, S D ^a   Finnell, R H ^b   Bennett, G D ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b TEXAS A AND M UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 AMINOBENZOTRIAZOLE; 1,4 BENZOQUINONE; CARBAMAZEPINE; CYTOCHROME P450; EPOXIDE HYDROLASE; GLUTATHIONE TRANSFERASE; PIPERONYL BUTOXIDE; POLYCYCLIC AROMATIC HYDROCARBON DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; STIRIPENTOL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOTRANSFORMATION; CONTROLLED STUDY; DNA ADDUCT; DRUG METABOLISM; FEMALE; LIPID PEROXIDATION; LIVER CYTOSOL; LIVER MICROSOME; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BINDING; TERATOGENICITY;

ANIMALS; ANTICONVULSANTS; ASCORBIC ACID; CAFFEIC ACIDS; CARBAMAZEPINE; CARBON MONOXIDE; CATECHOL O-METHYLTRANSFERASE; CYTOCHROME P-450 ENZYME SYSTEM; DIOXOLANES; ENZYME INHIBITORS; EPOXIDE HYDROLASES; FEMALE; GLUTATHIONE TRANSFERASE; MICE; MICE, INBRED STRAINS; MICROSOMES, LIVER; NAD(P)H DEHYDROGENASE (QUINONE); NADP; PIPERONYL BUTOXIDE; SULFHYDRYL COMPOUNDS; TRIAZOLES;

ANIMALIA; ARENA; ARENE;

EID: 0029862598     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. L. Gram and P. K. Jensen: Carbamazepine toxicity. In "Antiepileptic Drugs" (R. H. Levy, R. Mattson, B. Meldrum, J. K. Penry, and F. E. Dreifuss, eds.), pp. 555-565. Raven Press, New York, 1989.
2. K. L. Jones, R. V. Larco, K. A. Johnson, and J. Adams: Pattern of malformations in the children of women treated with carbamazepine during pregnancy. N. Engl. J. Med. 320, 1661-1666 (1989).
3. F. W. Rosa: Spina bifida in infants of women treated with carbamazepine during pregnancy. N. Engl. J. Med. 324, 674-677 (1991).
4. A. J. Bengt-Källén: Maternal carbamazepine and infant spina bifida. Reprod. Toxicol. 8, 203-205 (1994).
5. D. Lindhout, R. J. E. A. Hoppener, and H. Meinardi: Teratogenicity of antiepileptic drug combinations with special emphasis on epoxidation of carbamazepine. Epilepsia 25, 77-83 (1984).
6. S. Kaneko, K. Otani, Y. Fukushima, Y. Ogawa, Y. Nomura, T. Ono, Y. Makane, T. Teranishi, and M. Goto: Teratogenicity of antiepileptic drugs: Analysis of possible risk factors. Epilepsia 29, 459-467 (1988).
7. B. M. Kerr and R. H. Levy: Unsubstituted amides: New class of potent inhibitors of human microsomal epoxide hydrolase. Drug Metab. Dispos. 18, 540-543 (1990).
8. M. Pirmohamed, N. R. Kitteringham, T. M. Guenthner, A. M. Breckenridge, and B. K. Park: An investigation of the formation of cytotoxic, protein-reactive and stable metabolites from carbamazepine in vitro. Biochem. Pharmacol. 43, 1675-1682 (1992).
9. D. M. Jerina and J. W. Daly: Arene oxides: A new aspect of drug metabolism. Science 185, 573-582 (1974).
10. G. B. Gordon, S. P. Spielberg, D. A. Blake, and V. Balaxubramanian: Thalidomide teratogenesis: Evidence for atoxic arene oxide metabolite. Proc. Natl. Acad. Sci. U.S.A. 78, 2545-2548 (1981).
11. E. Dybing and S. D. Nelson: Metabolic activation of methyldopa and other catechols. Arch. Toxicol. 1, (Suppl.) 117-124 (1978).
12. S. D. Nelson, J. R. Mitchell, E. Dybing, and H. A. Sasame: Cytochrome P-450-mediated oxidation of 2-hydroxyestrogens to reactive intermediates. Biochem. Biophys. Res. Commun. 70, 1157-1165 (1976).
13. S. M. Furst and J. P. Uetrecht Carbamazepine metabolism to a reactive intermediate by the myeloperoxidase system of activated neutrophils. Biochem. Pharmacol. 45, 1267-1275 (1993).
14. K. Lertratanangkoon and M. G. Horning: Metabolism of carbamazepine. Drug Metab. Dispos. 10, 1-10 (1982).
15. J. W. Faigle and K. F. Feldman: Carbamazepine biotransformation. In "Antiepileptic Drugs" (R. H. Levy, R. Mattson, B. Meldrum, J. K. Penry, and F. E. Dreifuss, eds.), pp. 491-504. Raven Press, New York, 1989.
16. R. H. Finaell, G. D. Bennett, J. T. Slattery, B. M. Amore, M. Bajpai, and R. H. Levy: Effect of treatment with phenobarbital and stiripentol on carbamazepine-induced teratogenicity and reactive metabolite formation. Teratology 52, 324-332 (1995).
17. C. D. Campbell and C. W. Rees: Synthesis and oxidation of 1- and 2-aminobenzotriazole. J. Chem. Soc. C, 742-747 (1969).
18. S. S. Gill, K. Ota, and B. D. Hammock: Radiometric assays for mammalian epoxide hydrolases and glmathione-S-transferases. Anal. Biochem. 131, 273-282 (1983).
19. O. H. Lowry, N. J. Rosebrough, A. L. Farr, and R. J. Randall: Protein measurement with the folin phenol reagent. J. Biol. Chem. 193, 265-275 (1951).
20. T. Omura and R. Sato: The carbon monoxide binding pigment of liver microsomes. I. Evidence for its hemoprotein-nature. J. Biol. Chem. 239, 2370-2378 (1964).
21. B. M. Kerr, A. E. Rettie, A. C. Eddy, P. Loiseau, M. Gyout, A. Wilensky, and R. H. Levy: Inhibition of human liver microsomal epoxide hydrolase by valproate and valpromide: In vitro/in vivo correlation. Clin. Pharmacol. Ther. 46, 82-93 (1989).
22. R. N. Wixtrom and B. D. Hammock: Membrane-bound and soluble fraction epoxide hydrolases. In "Biochemical Pharmacology and Toxicology" (D. Zakim and D. A. Vessy, eds.), vol. 1, pp. 1-93. John Wiley & Sons. New York, 1985.
23. D. G. Kleinbaum, L. L. Kupper, and K. E. Muller: "Applied Regression Analysis and Other Multivariable Methods," ed. 2, pp. 361-372. PWS-Kent Publishing Co., Boston, 1988.
24. J. Seidegard and J. W. DePierre: Microsomal epoxide hydrolase properties, regulation and function. Biochim. Biophys. Acta 695, 251-270 (1983).
25. R. Jung, P. Bentley, and F. Oesch: Influence of carbamazepine-10,11-oxide on drug metabolizing enzymes. Biochem. Pharmacol. 29, 1109-1112 (1980).
26. N. H. Shear, S. P. Spielberg, M. Cannon, and M. Miller: Anticonvulsant hypersensitivity syndrome: In vitro risk assessment. J. Clin. Invest. 82, 1826-1832 (1988).
27. J. A. Hinson and D. W. Roberts: Role of covalent and noncovalent interactions in cell toxicity: Effects on proteins. Annu. Rev. Pharmacol. Toxicol. 32, 471-510 (1992).
28. S. D. Nelson and P. G. Pearson: Covalent and noncovalent interactions in acute lethal cell injury caused by chemicals. Annu. Rev. Pharmacol. Toxicol. 30, 169-195 (1990).
29. M. Pirmohamed, N. R. Kitteringham, A. M. Breckenridge, and B. K. Park: The effect of enzyme induction on the cytochrome P450-mediated bioactivation of carbamazepine by mouse liver microsomes. Biochem. Pharmacol. 44, 2307-2314 (1992).
30. F. Oesch, J. Doehmer, T. Friedberg, H. R. Glatt, B. Oesch-Barlomowicz, K. L. Platt, P. Steinberg, D. Utesch, and H. Thomas: Toxicological implications of enzymatic control of reactive metabolites. Hum. Exp. Toxicol. 9, 171-177 (1990).